Information de reference pour ce titreAccession Number: | 00003455-201006000-00049.
|
Author: | Guslandi, Mario
|
Institution: | M. Guslandi Gastroenterology Unit, S. Raffaele University Hospital, Milan, Italy e-mail: [email protected]
|
Title: | Rifaximin for Inflammatory Bowel Disease.[Letter]
|
Source: | Digestive Diseases & Sciences. 55(6):1805, June 2010.
|
References: | 1. Shafran I, Burgunder P. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity. Dig Dis Sci. 2010;55:1079-1084.
2. Day AS, Gearry RB. Rifaximin and Crohn's disease: a new solution to an old problem? Dig Dis Sci. 2010;55:877-879.
3. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54.
4. Tamboli CP, Neut C, Desremeaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut. 2004;53:1-4.
5. Guslandi M, Giollo P, Testoni PA. Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: preliminary clinical experience. Curr Ther Res. 2004;65:292-296.
6. Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis. 2006;12:335.
7. Guslandi M. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. J Clin Gastroenterol (in press).
|
Language: | English.
|
Document Type: | CORRESPONDENCE.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0163-2116
|
NLM Journal Code: | ead, 7902782
|
DOI Number: | https://dx.doi.org/10.1007/s1062...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |